Abstract To describe factors associated with preimplantation genetic diagnosis (PGD) decisions among Jewish Israeli BRCA1/2 carriers or spouses of a male carrier, we contacted all women who initiated PGD consultation for embryonic BRCA1/2 mutation detection at Sheba Medical Center, prior to March 2014. Applying a qualitative approach, we asked women to elaborate on the factors they considered in either opting for PGD or discontinuing the screening procedure. Participants were 18 Jewish Israeli women; 14 were carriers of one of the Ashkenazi founder mutations in BRCA1/2, and four were spouses of male mutation carriers, who underwent at least one cycle of PGD. Prior to seeking PGD, ten of the women had no children. At the time of the interview, all but three had at least one child. Three factors emerged as key motivators for PGD: having witnessed the disease in a close relative (n = 12); prior IVF treatment for infertility (n = 12); and having pre-existing frozen embryos (n = 6). Ten women withdrew from the PGD process due to clinical, logistical, and financial reasons. In conclusion, most women decided to withdraw from PGD instead of continuing until a successful conception was achieved. Those who opted for PGD attributed their discontinuation of further screening to the emotional burden that is greatly intensified by practical difficulties.
Introduction
In 2006, both the UK Human Fertilization and Embryo Authority (HFEA) and the Israel Ministry of Health approved measures to allow preimplantation genetic diagnosis (PGD) for BRCA1 and BRCA2 mutations (HFEA 2006; Israel Ministry of Health Directive 2006) . PGD aims to detect embryos for mutations harbored by the parents; it is performed by studying a cellular biopsy taken from a developing human embryo, acquired via in vitro fertilization (IVF) (Brezina et al. 2012) .
In the Ashkenazi Jewish population, three predominant mutations in BRCA1 (185delAG, 5382InsC) and BRCA2 (6174delT) account for the majority of hereditary breastovarian cancer syndrome. The lifetime risk of developing the disease for female mutation carriers reaches 60-80% and 16-50% for breast and ovarian cancer, respectively (King et al. 2003; Simchoni et al. 2006) . BRCA1/2 mutations have also been associated with pancreatic, prostate, colorectal cancers, and melanoma, though the precise lifetime risk and the extent of the association are unclear (Sopik et al. 2015) . Breast cancer in BRCA1/2 mutation carriers is often diagnosed at an early age, occasionally as an aggressive, bilateral disease (Anders et al. 2008; Comen et al. 2011; Metcalfe et al. 2011; Robson et al. 2004; Southey et al. 2011; Young et al. 2009 ). Therefore, mutation carriers are advised to maintain intensive follow-up; female mutation carriers are advised to consider risk-reduction surgeries, primarily prophylactic bilateral salphingo-oophorectomy (Eisinger et al. 1998; Hartmann et al. 2004; Schwartz et al. 2009 ).
Two options are available to prevent the transmission of the BRCA1/2 mutation to the next biogenetically-related generation. First is prenatal diagnosis (PND), performed by chorionic villus sampling (CVS) or amniocentesis during pregnancy; it enables women to terminate the pregnancy if the fetus is found to carry a mutation. CVS entails sampling of placental tissue and is usually performed at the first gestational trimester, while amniocentesis is an analysis of amniotic fluid, usually carried out in the second trimester. The estimates of pregnancy loss attributable to these invasive procedures are about 2% and 1%, respectively (Akolekar et al. 2015) . A second option is preimplantation genetic diagnosis (PGD), in which embryos are generated via in-vitro fertilization (IVF) and genotyped, enabling selective transfer of unaffected embryos to the uterus (Ao et al. 1998) . With the popularization of these diagnostic procedures, their use has expanded in several countries, from use only for syndromes of near-complete penetrance, to include late-onset susceptibility syndromes (e.g., breast and ovarian cancer) (Douma et al. 2010; Menon et al. 2007; Offit et al. 2006; Robertson 2003) .
Previous studies on attitudes towards PGD and PND in high-risk breast-ovarian cancer families and BRCA1/2 mutation carriers reveal great variability. In a survey of BRCA1/2 mutation carriers by Menon et al. (2007) , 75% of participants (n = 52) agreed that PGD should be offered to high risk individuals. Yet, among women who were planning pregnancy, only one in seven indicated that they would personally consider PGD. Vadaparampil et al. (2009) conducted a cross-sectional web-based survey among 471 BRCA1/2 mutation carriers and 383 family members. Of 318 participants who stated that they would consider PGD, 140 (44%) were BRCA1/2 mutation carriers, and 39% were non-carriers; the remaining participants either carried BRCA1/2 variants (13.5%) or were of unknown carrier status (3.5%). Similarly, in a study conducted in Spain, 48% of 77 individuals stated they would consider PGD, when asked on their first risk-assessment visit prior to BRCA1/2 testing (Fortuny et al. 2009 ). Likewise, in the study conducted by Quinn et al. (2009) , 57% of 111 women who had hereditary breast and ovarian cancer, found PGD an acceptable option, while 33% stated they would consider the procedure, and 42% of women would not. Staton et al. (2008) studied 213 BRCA1/2 mutation carriers with a mean age of 34 years; although most participants (88%) reported high levels of concern regarding transferring the mutation to their children, only 13% were likely to consider PGD.
It appears that members of high risk breast-ovarian cancer families view PGD as an acceptable option, yet relatively few would consider going through the procedure. Furthermore, although both PGD and PND procedures raise ethical concerns regarding selecting and labelling embryos (Aarden et al. 2009; Werner-Lin et al. 2012 ), women at high-risk for breast-ovarian cancer clearly prefer PGD over PND as a way to avoid the prospect of pregnancy termination (Derks-Smeets et al. 2014; Menon et al. 2007; Ormondroyd et al. 2012; Quinn et al. 2010 Quinn et al. , 2012 .
Only a handful of studies have focused on the actual decision-making process of BRCA1/2 carriers and the clinical, reproductive, logistic and financial issues raised during the PGD process. In these qualitative studies, women expressed concerns over selecting embryos, and they were deterred by the need to undergo IVF. While couples affirmed that they had prepared themselves for the physical burden and the practical impact of the IVF-PGD treatments, they had been unable to anticipate the psychological strains they experienced (DerksSmeets et al. 2014; Hurley et al. 2012; Ormondroyd et al. 2012; Rubin et al. 2014; Werner-Lin et al. 2012 ). According to a report by Hadassah Medical Center (Jerusalem, Israel) on the first two years following the approval of measures to allow PGD for late onset diseases, IVF-PGD was applied by six of the ten carrier women in the study cohort, while none of the BRCA1/2 mutation carriers considered PND (Sagi et al. 2009 ).
Purpose of the Study
In this study, we recruited women who are either BRCA1/2 carriers or the partners of male carriers that had initiated PGD consultation and undergone at least one cycle of PGD for the diagnosis of BRCA1/2 mutations. Our aim was to qualitatively identify the most influential factors considered by women in their decision either to undergo PGD or to refrain from additional embryo screening cycles.
Methods Participants
Between December 2007 and March 2014, 41 women approached the PGD unit in the Gynecology Outpatient Clinic, at the Sheba Medical Center (Ramat-Gan, Israel) for BRCA1/2-PGD consultation. These 41 women were contacted via phone and invited to participate in the study. Each woman was contacted a maximum of two times. Nineteen women were reached successfully, and they agreed to be interviewed for the study. Of these 19 women, 18 had undergone at least one cycle of PGD, while one decided not to pursue such screening. Given this distribution, our analysis focuses on the 18 women who underwent at least one PGD screening cycle. The remaining 22 women, who did not participate in the study, were either lost for follow up or declined our invitation; none of these women had undergone PGD.
The participants included 18 Ashkenazi Jewish Israeli women, either carriers of BRCA1/2 mutations (n = 14) or the partners of male mutation carriers (n = 4), who initiated consultation and carried out at least one PGD cycle for BRCA1/2 mutation detection. The women were all tested for BRCA1/2 in Genetic Institutes within Israeli hospitals, either after their non-PGD pregnancies, or after breast cancer diagnosis. None of the women were related.
Instrumentation and Procedure
The study was conducted between January 2013 and March 2014, after receiving institutional review board (IRB) approval. Each participant signed a written informed consent.
Applying a qualitative approach, women were asked to relate their motivation for deciding to explore and to carry out PGD to detect embryonal BRCA1/2 mutations, or discontinue this screening procedure. In the case of our study, using the qualitative research perspective illuminates the experiences of the young women who grappled with the risk of transferring a BRCA1 or BRCA2 mutation to their offspring (Moustakas 1994; Renzetti and Lee 1993) . The study was carried out by semi-structured interviews which were conducted by an experienced interviewer. The interviews were conducted face-to-face at a location of the participants' choosing, averaged an hour in length, and they were audio-recorded with permission.
The interview guide included three sets of questions: informative questions about the woman's socio-demographic profile; her reproductive and medical history (e.g., questions regarding previous fertility treatments, genetic testing for BRCA1/2 mutations, family cancer history and follow up practices); and questions regarding PGD and PND (e.g., have the procedures been brought up by any of the experts following BRCA1/2 diagnosis?) as well as reasons for seeking expert advice and eventually deciding to perform PGD or to decline additional screening cycles, including ethical considerations. Additionally, participants were asked to describe their physical and emotional burden while undergoing PGD.
Data Preparation and Analysis
We conducted a thematic content analysis based on the grounded theory approach. Data analysis was performed both inductively and recursively, using the phenomenological paradigm (Moustakas 1994) to unveil preferences and motives to opt for and follow PGD for BRCA1/2 screening, or to refrain from doing so. The following steps in the data analysis process were conducted in order to identify thematic lines in the women's accounts (Renzetti and Lee 1993) :
(1) Open coding. Each interview was coded twice, by the first and third authors, independently, to capture themes emerging from the data. Common themes and patterns were noted, and key linkages were identified in the data, indicating similar instances of the same phenomenon. (2) Axial coding. In a second reading of the transcripts, relationships between themes and sub-themes were gradually identified by context and content. The completed interviews were all compared to consolidate meanings and devise a concept construct (Strauss and Corbin 1998) . (3) Integration. The findings were grouped under broader categories. Quotations from participant narratives comprised the grounded interpretations (Lincoln and Guba 1985) .
Results

Participant Characteristics
The socio-demographic characteristics of the women are presented in Table 1 . Fourteen of the 18 women were carriers of one of the three Ashkenazi founder mutations in BRCA1/2, and four were spouses of male carriers. Of the carriers, six were diagnosed with breast cancer prior to recruitment. The women's ages ranged from 24 to 41 when interviewed. By their self-reported incomes, the women were middle class, while 12 of the 18 women reported an aboveaverage income. All were married, and all but three had at least one child at the time of the interview. All women reported an undergraduate or higher academic degree. Three women were religious (i.e., followed the Jewish traditional commandments) (Tables 1 and 2 ).
Themes and Categories in Interview Responses
The subsequent findings are presented in two sections. The first outlines the factors women associated with their choice to opt for PGD. The second describes the factors women mentioned as underlying their decisions to decline additional PGD cycles, even when the previous attempts were unsuccessful (Table 2 ). All women are presented with assumed names.
Opting for PGD: Facilitating factors
Three significant factors emerged as central in women's decisions to opt for PGD for BRCA1/2 mutation detection: (1) Having witnessed breast-ovarian cancer in a close relative; (2) Prior IVF treatment for infertility; and (3) Having preexisting frozen embryos.
Having witnessed breast-ovarian cancer in a close relative (n = 12/18)
Women who witnessed a close relative struggling with breast or ovarian cancer mentioned this experience as a key motivation for undertaking PGD. Attara, whose mutation was inherited from her father, described her family's experience:
BMy paternal grandmother died of cancer, and then my father's aunt was diagnosed with cancer. I am a carrier, and the aim [in performing PGD] is not to pass it [the mutation] on.Â ttara drew a direct line between witnessing the disease in her close relatives and initiating PGD. Possibly, observing the suffering around her and experiencing the anxiety of elevated risk, prompted her -at the age of 35, healthy, married without children -to take active measures to prevent a similar future for her offspring.
Direct witnessing was not, however, necessary. Several wives of male carriers expressed even greater determination to avoid passing on the mutation. Rona, aged 24, healthy, married without children at the time of interview, associated her PGD decision directly with her partner's family history:
BThe cancer cases in his [her husband's] family ended badly. His mother and sister were diagnosed with ovarian cancer, and I don't think that we have to live with this death sentence… it is a great opportunity to create a new branch that is free of this gene [mutation] .^R ona, thus, referred to PGD as an opportunity to discontinue her husband's cancer family history, and protect her future children from the destiny of illness and worry. Similar grounds for PGD were offered by Leah, another healthy woman aged 33, married with one son. Leah also noted the cancer in her husband's family as her motivation to undergo PGD: BIf I have a daughter, I don't want her to suffer.Î n some cases, the road to PGD was more complex. Fania, aged 30, was interviewed during her first pregnancy following IVF-PGD. For her, too, her husband's family history of breastovarian cancer was a major contributor for undergoing PGD. However, Fania and her partner also had fertility difficulties. Ironically, these latter difficulties have rendered PGD more accessible, as the couple was eligible for publicly funded IVF and had to pay only for the PGD component. In Fania's words:
BWe decided to undergo PGD [because] my husband's mother died at 42 from breast cancer. His grandmother died when she was forty, also from breast or ovarian cancer -he never knew her.Ĥ aving a close relative who struggled with cancer at a young age emerged as a strong reason that impelled BRCA1/ 2 carriers to opt for PGD; they wanted to ensure that their babies, especially the girls, would be mutation free. However, powerful as the cancer history was, the road to PGD was accompanied by conflicts and fears. The difficulty No of initiating IVF only for PGD, emerged from the words of the mutation carrier women who did not require IVF to treat infertility. Shira's mother had died of ovarian cancer, and she herself was diagnosed with breast cancer at 34, several months after giving birth to her second daughter. Shira expressed her concern about undergoing IVF solely for the purpose of PGD:
BI experienced too much pain and death from this [BRCA mutation] carriership and I feared it…On the one hand, it was important for me not to transfer the mutation; on the other hand, IVF itself is risky… it is a horror cycle.1
.2 Prior IVF treatment for infertility (n = 12/18)
Most women in our sample had experienced fertility difficulties prior their decision to undergo PGD. Our interviews revealed that having undergone IVF irrespective of PGD highly influenced these women's decisions. Ella, a healthy, 39-year-old carrier was clear about the connection: BI don't know if I would have done it [PGD] otherwise, but it was easier to select this option because I underwent IVF anyway [due to infertility].M iriam's depiction was quite similar. When she and her husband first realized that they would have to undergo IVF, they searched for a clinic that could administer PGD as well. Rebecca's mother and aunt were diagnosed with breast cancer in their forties, and other family members also had cancer. Rebecca herself was diagnosed with breast cancer when she was 35, during IVF treatment. Rebecca spelled out her hierarchy of PGD motivations: B[The cancer in the family] was not the main reason. For me, I did PGD because I had to undergo IVF.Ŵ hereas all women wished for a healthy non-carrier baby, those who had required IVF treatment irrespective of the mutation, mentioned the fertility treatment as the reason that greatly promoted their decision to embark on PGD.
Having pre-existing frozen embryos (n = 6/18)
Possibly the most immediate trigger for PGD was the existence of frozen embryos from previous IVF cycles. Six of the women in our sample had frozen embryos from either fertility preservation procedures prior chemotherapy or due to infertility. Five of the six associated their PGD decision with the pre-existing frozen embryos. Batia's two children were born spontaneously after she had been treated for breast cancer at the age of 24. When she planned her third pregnancy, she initiated a PGD consultation, seeking to test the embryos from her pre-chemotherapy fertility preservation measures. When she had not conceived, Batia did not pursue additional cycles of IVF-PGD to create new embryos and have them tested. Thus, it appeared that the pre-existence of the embryos prompted Batia to opt for PGD.
Hanna provided the most direct depiction of the crucial role of pre-existing embryos. Having had one daughter following IVF treatments, and another after a spontaneous pregnancy, Hanna, a 41 year-old healthy carrier, and her husband decided to test the embryos they had from a previous IVF cycle. When the tested embryos did not survive for implantation, the couple decided Bthat two healthy daughters are enough^and did not try to conceive anymore.
Summary
Whether due to witnessing breast-ovarian cancer in relatives or being personally diagnosed with the disease, or because they had cryopreserved embryos or needed IVF performed for infertility, the fear of transferring a BRCA1/2 mutation to offspring prompted the women in the current study to opt for PGD counseling and to go through the procedure. It appears that this fear overcame the ethical concerns of creating Ba designer baby.^When women were directly asked about the ethical issues, their answers ranged between complete disagreement (n = 12), saying: BWhat? Am I choosing a blond child? I choose a healthy child,^to BYes, I could imagine that people think this is intervening with fate (n=6). Only one woman said the PGD^might be a problem.2 .
Discontinuing PGD: Deterring factors
Reservations from PGD were clinical, as well as logistic and financial. Four women in our sample conceived, and another woman had a baby via gestational surrogate, with tested, mutation-free embryos. Altogether, at the time of the interview, five of the 18 women who have performed PGD, had children following the procedure; three women pursued additional screening cycles after they had not conceived. The remaining ten women did not perform additional PGD cycles though they had not conceived (Table 2) .
Clinical deterrents (n = 8/10)
A recurrent clinical factor, that eight women mentioned as a reason for discontinuing PGD, was the decrease in the likelihood of conception. Alona, a 38-year-old healthy wife of a mutation carrier man, was undergoing IVF on grounds of infertility. Alona has undergone one cycle of PGD and did not conceive. The couple went on with fertility treatments for four years and eventually had a son, without PGD. Alona attributed their withdrawal from PGD to the decrease in the embryo quality due to the PGD procedure, and the subsequent decreased chance of conception. The painful tension between the desire to have a baby and the attempt to ensure that the baby was mutation free, imbued Galia's account. Galia, a 39-year-old woman and mother of two children born before her diagnosis, tested the 15 embryos she and her partner had from her fertility preservation cycle. Her description captured the sense of missed opportunity following PGD:
BWe thawed our frozen embryos, only one embryo had survived, and it was a carrier… I stopped with this [PGD] , disappointment follows disappointment… maybe it is better to have a carrier child, than not to get pregnant at all… In retrospect, I regret [having done PGD].F rom these women's accounts, the decision to proceed or discontinue PGD emerged as a painful intersection between weighing the risk of having a mutation carrier baby against the risk of not having a baby at all. The women in our sample, who brought up this balance, eventually prioritized conception over screening. For these women, while natural conception may improve the chances to conceive, it may still result in disappointment if pregnancy is not achieved, or due to worry accompanying the birth of a mutation carrier child.
Logistic and financial burden (n = 7/10)
Seven women dwelled on the logistic and financial difficulties as underlying their decisions to discontinue PGD. Two women, who decided to continue with PGD after they had not conceived, discussed the logistic and financial toll. For five women, these difficulties were added to the hardship of repeated clinic visits that IVF entailed, finally resulting in the decision to refrain from PGD.
Lea emphasized the practical effort:
BIt [PGD] took a lot of energy… I could have managed with the injections and the oocyte retrieval, and the transfer… but the everyday checkups… the stress to get the medications in time… and the work I had missed… It takes a lot of strength.F or Daniella, the geographical distance rendered the burden unbearable:
BWe were referred to a hospital near Tel Aviv. Now, we live up north... Then, the nightmare began… The daily checkups and phone calls for further instructions… I felt that we have to live there [near the clinic], otherwise it would be a nightmare.^T he logistic burden was often accompanied by a financial drain. Israel's Ministry of Health allows BRCA1/2 mutation detection via PND and PGD but does not fund the procedure (Israel, Ministry of Health Directive) . Rita, a religious woman aged 24, married without children, received significant financial support for PGD from her parents. She said she would not have been able to afford the treatment otherwise, and she wondered how other people managed. Rachel was critical of the price, claiming that:
BIt is important that people who want to undergo PGD and give birth to a 'healthy' [non-BRCA1/2 carrier] child will have the chance to do so without taking a 'mortgage' …. Notably, none of our participants found the option of PND an acceptable mode for screening.
Upon conclusion, we should take a look at a successful PGD procedure. Bracha was diagnosed with breast cancer at 26. Two years after she had completed cancer treatments, her husband said that PGD was the greatest gift he could give his child. Fourteen ova were harvested; one embryo developed and was mutation free. The implanted embryo eventually divided into twins.
Discussion
The main conclusion of this study, even if tentative and preliminary, is that PGD is a highly demanding procedure for women. The vast majority of our respondents (16/18) either had frozen embryos from pre-chemotherapy fertility preservation treatments or IVF performed due to fertility problems. Only two women initiated IVF exclusively for the purpose of BRCA1/2-PGD. Once they Bran out^of existing embryos, ten couples withdrew from PGD even though conception was not attained. Apparently, women who experienced fertility problems were reluctant to reduce their chance of conception by performing PGD, whereas fertile women tended to refrain from IVF if they were not compelled to do so to treat infertility.
As reported in previous studies (Derks-Smeets et al. 2014; Menon et al. 2007; Quinn et al. 2009 Quinn et al. , 2012 Werner-Lin et al. 2012) , the participants were motivated first and foremost by the wish not to pass the mutation on to offspring, and to secure a future free of the BRCA1/2 mutations-prompted anxiety and substantial cancer risk for their children, via PGD. However, none of our interviewees found the option of PND appropriate. This finding suggests that women who sustained infertility or cancer, once pregnant, found the prospect of pregnancy termination due to BRCA1/2 carriership so deterring, that they prioritized the desire to be a parent over the fear of giving birth to a child carrying a BRCA1/2 mutation.
Notably, when they recounted their reluctance to pursue the screening procedure, our interviewees hardly mentioned ethical concerns. The debate around Bdesigner babies,^that often adjoins PGD (Aarden et al. 2009; Franklin and Roberts 2006; Werner-Lin et al. 2012) , did not seem to play a significant role for women in the present study. Though they were asked directly about this issue, the women perceived the cancer threat as so menacing, that they marginalized more distant, abstract ethical ambiguities from their decision making. Indeed, when women detailed the reasons that had deterred them from obtaining additional PGD cycles, ethical concerns were mentioned in passing, if at all.
The financial difficulty was crucial for four participants in the present study. IVF/PGD has been shown as cost-effective in preventing most births of individuals with debilitating early-onset genetic diseases (Handyside 2010; Tur-Kaspa et al. 2010) . Western countries, such as France, Spain, The Netherlands, Germany, and United States, do not fund PGD/PND for BRCA1/2 detection (Aarden et al. 2009; Julian-Reynier et al. 2009; NHS Commissioning Board 2013) . Given the low frequency of BRCA1/2 mutation carriers, it seems plausible that PGD for BRCA1/2 mutations might also be cost effective. In Israel, the IVF component is covered by the public Health Insurance, but only for couples with fertility problems. Otherwise, one cycle of IVF costs about 15,000-20,000 NIS (~$4500), and PGD adds about 10,000 NIS (~$2500). Thus, for couples in the present study with no fertility problems, the financial burden associated with pursuing PGD placed it beyond reach, especially when multiple cycles were needed. Consider the words of Fania, who said with irony, that Bwe were 'fortunate' to have fertility problems and an indication for IVF, so we paid only for the PGD part.^The concomitant logistic hurdles further added to the couples' difficulties, intensifying the emotional toll that PGD placed on the women (Drazba et al. 2014) .
Interestingly, of 41 women who initiated PGD appointments, 19 women (46%) were successfully contacted, and 18 of these women had undergone at least one cycle of IVF-PGD. Though we are unable to provide a well-grounded explanation for the reasons the women who decided not to pursue PGD were lost to follow-up, it may be suggested that the ones who did pursue PGD were more tightly connected to the clinic, and therefore easier to locate.
Study Limitations
This study has several limitations that should be pointed out: the sample size is small, it was conducted in a single medical center, and includes only Jewish, mostly affluent, Ashkenazi women. We do not have information regarding the women who were lost to follow-up or declined our invitation to participate in the study; in the absence of these data, we cannot characterize or distinguish the non-participants by any clinical or sociodemographic features. The study was conducted in Israel, where IVF is fully covered by the National Health Insurance for women with fertility difficulties. In this respect, this study is context specific for the health system in Israel. Finally, the group is heterogeneous as it includes both breast cancer survivors and cancer-free mutation carriers, as well as spouses of male BRCA1 or BRCA2 carriers. While our sample was too small to pinpoint thematic differences among these subgroups, future studies may elucidate this aspect. Despite these limitations, our findings provide perspectives on the actual processes women go through regarding PGD, both on the personal level and in practice.
Implications for Genetic Counseling Practice
Women's accounts reveal that genetic counselors may play key roles as providers of guidance and support for couples who desire to ensure they do not transfer a BRCA1 or BRCA2 mutation to their offspring. Genetic counselors can assist couples in grappling with the clinical, logistic and financial difficulties that PGD entails. Increased awareness and understanding of how women, who are BRCA1/2 mutation carriers or the partners of male carriers, experience and manage PGD, can improve quality of care. Genetic counselors and other healthcare providers may be able to use the present results as a basis for better informed guidance for such couples, regarding the overall PGD process, as well as the decision making intersections. Moreover, since PGD also involves substantial psychological dynamics, Bcarrier couples^may benefit from personally tailored support services that include genetic counseling by personnel who specialize in PGD.
Conclusion and Research Recommendations
Though limited in scope, and therefore preliminary, the current findings illustrate how women and couples embarked on PGD in the hope of securing a healthier future for their offspring. Yet, the majority of these Breproductive technology pioneers^ (Rapp 1987) , were apparently deterred by the complexities that accompany this form of repro-genetic technology, and discontinued the screening procedure even if they had not conceived. The users who eventually opted out of PGD attributed their withdrawal to the emotional burden that PGD entailed, and the concomitant practical difficulties. Further research should be conducted in other PGD clinics in Israel and elsewhere, in order to validate these findings. Another complementary perspective would be a comparison of women's PGD accounts according to the cause that underlay the screening. Such research might also investigate whether genetic counselors' recommendations and decision making processes vary according to the particular cause for which PGD is performed.
